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Abstract Neospora caninum is widely recognized as one
of the most important infectious organisms causing abor-
tion and stillbirth in cattle. This parasite causes severe
economical losses worldwide. Infection is mostly passed
vertically from mother to calf during pregnancy. Under
certain circumstances, an infection can lead to abortion, but
in most cases it results in a chronically infected calf, which
itself will represent the next endogenously infectious
generation. So far, no reliable therapeutic or metaphylactic
tool has been developed. One possibility to control the
problem may consist of treating newborn calves that
became vertically infected by a persistently infected
mother. This may allow parasite-free offspring. The aim
of the present study was to address the questions: (1) can
serology be used to assess efficiency of treatment in
toltrazuril-medicated animals? and (2) is a strategic
prevention measure possible by means of producing
N. caninum-free calves from positive cows? Calves from
Neospora-seropositive cows and heifers were randomly
split into two different medication groups: 36 calves were
medicated with toltrazuril and 36 calves obtained a
placebo. Medication (20 mg toltrazuril per kg bw) was
administered three times, every second day, within the
7 days post natum. Three months after medication, there
was no difference in antibody reactivity between the two
groups. At later time points (4–6 months), however,
significant differences were found, as explained by a
strong humoral immunity after chemotherapeutical affec-
tion of parasites, while the placebo-treated animals only
responded weakly to the persistent infection. In summary,
we concluded that (1) serology was not an entirely
appropriate tool to answer our initial question and (2)
toltrazuril has the potential to eliminate N. caninum in
newborn calves. As a consequence, we plan to follow up
toltrazuril-medicated calves clinically and serologically
over a longer period and investigate if they give birth to
Neospora-free calves.
Introduction
Neospora caninum is an important cause of infectious
abortion and stillbirth in cattle worldwide. Infection is
common and may frequently be passed on from mother to
calf (endogenous transmission) with no signs of disease.
Disease occurs when the parasite multiplies in the
developing calf and in the maternal and fetal placenta,
causing sufficient damage to trigger abortion or stillbirth
(Dubey and Lindsay 1996). Infection of the fetus early in
gestation is more likely to be fatal to the conceptus than
infection later in gestation (Dubey 2003). However, it also
appears that infection is more likely to be transmitted in late
rather than early pregnancy. Thus, the majority of
infections are not fatal, and, in this way, inapparent
infections are maintained in a herd. Endogenous transmis-
sion upon reactivation of dormant parasites is the major
route of prenatal infection, but it is also possible that
oocysts of N. caninum, produced by dogs and excreted in
their feces (McAllister et al. 1998), infect cattle if they
ingest contaminated food or water (exogenous transmis-
sion mode). Control of bovine neosporosis is difficult.
Although pharmaceutical preparations are known that will
affect N. caninum in vivo (Gottstein et al. 2005), there is
presently no validated and respectively registered ther-
apeutical strategy that can be recommended for practical
use to control the problem in the field, as referenced by
PubMed. The alternative—vaccinating cattle to efficiently
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control the problem—is still controversial and also lacks
proof of efficacy and efficiency (Andrianarivo et al. 2000;
Innes et al. 2002).
Experimentally, nevertheless, there has been a series of
studies that indicated some promising developments in
view to chemotherapeutically affect N. caninum in vitro
(Lindsay and Dubey 1989, 1990; Lindsay et al. 1994; Kim
et al. 2002; Kwon et al. 2003; Youn et al. 2003). In vivo,
the efficacy of treatment was less obvious, e.g., treatment
of mice with sulfadiazine and amprolium did not provide
sufficient effect (Lindsay and Dubey 1990). Toltrazuril, a
symmetric triazinon derivative, has been shown to affect
proliferating and resting stages of various coccidian
parasites (Mehlhorn et al. 1984; Greif 2000; Greif et al.
2001). The exact mode of action is still not yet fully
elucidated, but studies have shown that nuclear division is
affected, the mitochondrial activity is impaired, and the
endoplasmatic reticulum is vacuolized (Mehlhorn et al.
1984; Harder and Haberkorn 1989; Mitchell et al. 2005).
Explorative investigations had shown that toltrazuril can
be effective against experimental neosporosis in the murine
(Eperon et al. 1999; Gottstein et al. 2001; Darius et al.
2004) and bovine (Kritzner et al. 2002) model, and that an
efficient metaphylaxis requires at least a T-cell-mediated
immunological support in mice (Amman et al. 2004). We
now recently showed that toltrazuril can contribute to the
control of congenital neosporosis in mouse dams (Gottstein
et al. 2005). Besides reducing abortion and infertility rates
in pregnant mice, toltrazuril-treatment also affected directly
the infection course in the fetuses, which is best demon-
strated by the lack of postnatal death in offspring of
toltrazuril-treated mothers vs postnatal death of some of the
newborns of non-treated mothers (Gottstein et al. 2005).
Although infected dams may remain carriers of the
parasite, they seem not to act as sources of infection for
the fetus in later pregnancies, conversely to the situation
found in naturally infected cattle (Gottstein et al. 2005).
The present study was now designed to address the
following questions: (a) Does treatment of infected new-
born calves with toltrazuril, based upon the assumption that
the parasite load is eliminated, indirectly affect the course
of the humoral immune reaction of the host? A dichotomic
hypothesis was followed, in that a rapid elimination of the
parasite load should result in a temporally reduced serum
antibody reactivity, whereas a slow action should rather
transiently increase the respective anti-N. caninum anti-
body reactivity. The latter effect had already been described
after anti-coccidial treatment of poultry by toltrazuril. (b)
Can serology be used to assess efficiency of treatment in
toltrazuril-medicated animals?
The reason for choosing the (indirect) humoral immune
response as a follow-up parameter can be explained by the
lack of appropriate tools to reliably detect N. caninum in
vivo. Thus, the detection of parasite DNA in blood samples
(Okeoma et al. 2004) was discussed but was rejected, as
this approach does not provide a reliable way to
persistently distinguish between parasite carriers and
parasite-free animals. Even post mortem analyses of
various organs of naturally (Wyss et al. 2000) or
experimentally (Kritzner et al. 2002) infected animals
showed that the diagnostic sensitivity of PCR, when
compared to serology, was rather low, conversely to
abortion material, where an usually high infection intensity
can easily be detected by PCR.
The final control procedure we are anticipating with the
present strategy includes the following options: treatment
of newborn calves (from seropositive mothers) are relieved
from their N. caninum infection, thus, culling would not
anymore be necessary to obtain parasite-free offspring
breeding lines. The cost-effectiveness of such a strategy
may—beside the long-term reduction of the abortion rate—
be supplemented by the fact that this strategy would allow
to continue breeding of precious genetic lines, irrespective
of the mother’s infection status. The only alternative, so far,
has been to transfer embryos from seropositive donors into
seronegative recipient animals, a costly and time-consum-
ing procedure.
Furthermore, creating seronegative breeding lines may
also result in the improvement of other economic factors.
Thurmond and Hietala (1996) showed that seropositive
cows were earlier slaughtered than seronegative cows, and
that this effect was not only attributed to the abortion
problem but also to a reduced milk yield (Thurmond and
Hietala 1997; Hernandez et al. 2001, 2002). Some authors
even claimed a reduced gain of body weight in seropositive
fattening calves (Barling et al. 2000, 2001).
A successful treatment of newborn calves would have
further advantages to, e.g., treating adult cattle: the costs of
therapy are significantly lower as a cause of the lower body
weight and the withdrawal time of 63 days1 is not relevant
for newborn animals, compared to lactating cows. Upon
successful outcome of the present investigation, follow-up
studies are under design to prove that treated animals are
parasite-free.
Materials and methods
Gross study design
The present matched-pair and double-blinded study was
carried out under Good Clinical Practice (GCP) conditions.
In the first step, N. caninum seropositive cows were
preselected by ELISA (according to Sager et al. 2001) in 22
different cattle farms that had already been previously
investigated (Haessig and Gottstein 2002). The study was
run from May 2004 to March 2005. The farmer had to
inform the investigator about birth of calves from
designated seropositive cows immediately after delivery.
If feasible, the farmer or the investigator would draw an
umbilicord blood sample for subsequent pre-colostral
serological investigations (precS). Each calf underwent a
conventional clinical examination within 2 days post
partum, including assessment of body weight and a first
1 The recommended dosage for Baycox 5% oral suspension to treat
coccidiosis in cattle is 20 mg/kg once. Residue studies proved a
withdrawal period of 63 days after single treatment.
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post-colostral blood sampling (postcS_1). The mother
animal was simultaneously blood sampled as well. The calf
obtained the first dose of toltrazuril (Baycox 5% suspen-
sion: 20 mg totrazuril per kg body weight=vero) or placebo
(suspension without active ingredient) at the same time
point. A second identical dose was then applied 48 h later
and a third and last one 96 h later. A first follow-up blood
sample was drawn after approximately 3 months
(postcS_2). The respective mean time point was 104 days
after therapy (minimum 92 days; maximum 155 days).
Twenty-eight of the calves were kept longer in the farm,
thus, further samples were taken later (postcS_3 and
postcS_4), the latest at day 387 post therapy.
The calves were randomly clustered into two groups:
group I and group II. The affiliation of groups I and II to the
placebo and vero groups was released after accomplishment
of the experimental and analytical investigations. The
treatment distribution was assigned to all animals before
initiation of the study. An even number of calves was
included for each farm, so that each vero-treated animal had a
placebo-treated partner on the same farm (i.e., matched pair).
Toltrazuril blood serum concentration
Bood samples were collected from three placebo- and four
vero-treated calves between days 10 and 12 as well as 30
and 32 after medication, respectively. Respective serum
samples were stored frozen at −18°C till further use. After
thawing, the sera were deproteinized by mixing with
acetonitrile and subsequent centrifugation. Analysis for
concentrations of toltrazuril and toltrazuril–sulfone was
determined by HPLC with detection by tandem mass
spectrometry at the Laboratory for Animal Health, Bayer
CropScience AG, Research and Development, Develop-
ment, Residues, Operator and Consumer Safety, Monheim.
The limit of quantitation was 0.025 mg/l for each analyte.
Enzyme-linked immunosorbent-assay (ELISA)
Serum samples (n=143) were tested for detection of anti-N.
caninum antibodies by using a commercial ELISA test
CHEKIT at the laboratory of the Institute of Parasitology,
University of Bern, Switzerland, following the manufac-
turers’ instructions (Bommeli Diagnostics, Bern, http://
www.bommeli.com). This commercial test used microtiter
plates that were coated with crude antigen lysates of whole
tachyzoites. The test and control sera were diluted 1:10 and
incubated for 60 min at 37°C. Antibody reactivity was
measured by the degree of color developed (absorbance
measured at 405 nm, reference wavelength 490 nm). The
results were expressed as percent reactivities (= relative
antibody units, %rAU) using the following formula:
Sample value %rAUð Þ A sample F  Anegative
A positive F  Anegative 100
The factor F determined the cutoff and was calculated
from the mean absorption value of 40 N. caninum-negative
sera plus three standard deviations, divided by the absorp-
tion of the negative control (Anegative). Values above the
cutoff were defined as positive, those below as negative.
Sample values, expressed as relative antibody units (%
rAU), were, thus, brought into relation to the cutoff (0%
rAU) and the positive control (Apositive=100%rAU).
Serum samples were tested in triplicates. If the coeffi-
cient of variation was ≥0.10, the most divergent value was
ignored and the remaining two values were averaged. If
there were no outliners identifiable, all three values were
averaged.
Statistics
The software StatView 5.1 (SAS) was used to perform
analysis of variance and analysis of variance with repeated
measurements. The statistical analyses included only those
animals that had at least one seropositive result in the
whole series. Significant differences were determined with
a p value <0.05. Before applying parametric tests, the data
were checked for their normal distribution.
Results
Bodyweight of calves
The average bodyweight for the calves from the placebo
group was 44.4 kg (minimum 35 kg, maximum 59 kg) and
that for the vero group 44.4 kg (minimum 33.5 kg,
maximum 57 kg). There was no statistically significant
difference between both groups.
Serologies
Dam serology The mean serum reactivities of both groups
assessed by ELISA are shown in Fig. 1. There was no
statistically significant difference between both groups.
Precolostral calf serology Precolostral sera could be
obtained from 14 calves, from which eight samples were
seropositive by ELISA. From six calves that were
precolostrally seronegative, four seroconverted postcolosa-
trally, and two remained seronegative also postcolostrally,
although their mother had been seropositive at the
periparturient time point. The respective antibody reactiv-
ities of these two mother animals were very low, conversely
to the four other mothers (data not shown). The
postcolostral seroconversion and subsequent temporal
follow-up of antibody reactivities of the four periparturi-
ently seroconverting calves listed above are shown in
Fig. 2. Two of these four calves belonged to the placebo
group I, the other two to the vero group II. With the
exception of calf no. 31 (vero group), the other animals
exhibited a rapid decrease of antibody reactivities.
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Postcolostral calf serology Postcolostral follow-up of
antibody reactivities of the calves from groups I and II
are shown in Fig. 3. For all four time points (postcS_1,
postcS_2, postcS_3, and postcS_4), the comparison
between groups I and group II values provided no
statistically significant difference as assessed by analysis
of variance, although the mean values of group II appeared
slightly higher at the time points postcS_3 (p=0.19) and
postcS_4 (p=0.17).
Up to the time point postcS_2, four calves of group II
and one of group I had converted from initially seropos-
itive to now seronegative. At later time points, no more
calf converted to seronegative anymore.
Fig. 3 Boxplot of postcolostral follow-up of antibody reactivities
(expressed in relative antibody units, %rAU) of calves from group I
(placebo group) and group II (vero group). “postcS_1” refers to the
first postcolostral blood sampling at 1 to 3 days post partum (p.p.).
“postcS_2” refers to a blood sample drawn approximately 3 months
p.p. “postcS_3” and “postcS_4” refers to a total of 28 calves where
further samples could be taken at later time points (between 180 and
387 days p.p.)
Fig. 1 Boxplot of periparturient mean antibody reactivities of the
mother animals from group I (placebo group) and group II (vero
group). Antibody reactivities are expressed in relative antibody
units, %rAU (see text)
Fig. 2 Postcolostral follow-up of antibody reactivities (expressed in
relative antibody units, %rAU) of four calves that were precolos-
trally seronegative. Calves nos. 13 and 66 belonged to the placebo
group, calves no. 31 and 70 to the vero group. “postcS_1” refers to
the first postcolostral blood sampling at 1 to 3 days post partum
(p.p.). “postcS_2” refers to a blood sample drawn approximately
3 months p.p. “postcS_3” and “postcS_4” refer to a total of 28
calves where further samples could be taken at later time points
(between 180 and 387 days p.p.)
537
We subjected the postcolostral results altogether to an
analysis of variance with repeated measurements (Fig. 4).
With a p=0.048, the follow-up between postcS_1 and
postcS_3 / postcS_4, respectively, provided a statistically
significant difference between groups I and II. The
difference was obtained with an analysis of variance
(ANOVA) with repeated measurements using the respec-
tive A405 nm values as dependent variable, and time points
together with animal groups (I and II) as independent
variable, while the actual time point of sampling was used
as covariate. At the initial time point postcS_1, no
difference can be seen between groups I and II.
Subsequently, the two groups diverge in that the placebo
group (I) rapidly drops in antibody reactivity by each new
time point, whereas, the vero-group values remain high till
postcS_3, and then start to decrease till time point
postcS_4.
Toltrazuril blood serum concentration
Toltrazuril and toltrazuril–sulfone concentrations were
determined in the serum samples by HPLC-MS/MS and
provided the following findings: all samples from group I
(placebo group) were negative, therefore, no drug con-
centrations were detected in the samples.
The group II samples exhibited a mean toltrazuril
concentration of 31.7 mg/l (minimum 24.3, maximum
42.0) at the time points “10–12 days” and of 0.77 mg/l
(minimum 0.52, maximum 1.16) at the time points “30–
32 days”. The values for Toltrazuril–sulfone were 74.4 mg/
l (minimum 53.6, maximum 95.9) and 63.1 mg/l (mini-
mum 42.2, maximum 83.2), respectively.
Discussion
Within the range of potential means to control the bovine
N. caninum-induced abortion problem, chemotherapy of
newborn calves may reduce prevalence, provided the
treatment effectively results in parasite-free offsprings
(Haesler et al. 2006a, submitted for publication). Assessing
the costs and benefit of a control strategy, which considers
medical treatment of female offspring, resulted in a high
benefit–cost ratio (Haesler et al. 2006b, submitted for
publication). However, substances active against N. cani-
num are still under evaluation only, and their application
under defined experimental conditions deserves detailed
investigation and documentation before being proposed for
field application. Within such investigations, we designed
the present study to address the question if treatment of
infected newborn calves with toltrazuril affects the course
of the humoral immune reaction of the host. Immune
parameters may become an important parameter in
following-up experimentally treated cattle, as the direct
determination of the parasite load and the parasite viability
upon treatment is not possible in vivo.
In our experiments, 3 months after treatment of newborn
calves either with vero or placebo, there was no difference
in antibody reactivity between the two groups. As all calves
were born from N. caninum-seropositive mothers, they all
obtained a colostral passive immunity, including the four
calves that exhibited a negative precolostral serology. The
half-life period of such IgG is approximately 20 days, thus,
we cannot expect a full negativation within 3 months, thus,
colostral antibodies may exhibit a marked influence on the
humoral immune status the earlier after birth tests are
carried out. However, at a later time period (4–6 months),
we were able to demonstrate significant differences, as
shown by a stronger antibody reactivity expressed in vero-
treated animals when compared to placebo-treated calves.
This may be explained by the induction of a strong humoral
immunity after chemotherapeutical affection of parasites,
while the placebo-treated animals only responded weakly
to the persistent infection. At this time point, colostral
antibodies, quantitatively, do not play a crucial role
anymore. That humoral immunity raises after successful
treatment with toltrazuril was shown in the avian coccid-
iosis model by Greif (2000). Furthermore, we have found
in the murine model that toltrazuril-treatment requires
the support of host immunity to successfully eliminate
the parasite burden (Amman et al. 2004). Conversely, the
treatment of mice with toltrazuril did not interfere with the
development of a specific cellular intestinal immune
response to Eimeria falciformis, another coccidian parasite
affecting mice (Steinfelder et al. 2005). Still in the mouse
model, besides reducing abortion and infertility rates in
pregnant mice, toltrazuril-treatment also affected directly
the infection course in the fetuses, which is best demon-
strated by the lack of postnatal death in offspring of
toltrazuril-treated mothers vs postnatal death of some of the
newborns of non-treated mothers (Gottstein et al. 2005).
Although infected dams may remain carriers of the
parasite, they seem not to act as sources of infection for
Fig. 4 ANOVA analysis with repeated measurements (p value
<0.05) of antibody reactivities (expressed in relative antibody units,
%rAU; mean and standard error) of calves from group I (placebo
group) and group II (vero group) analysed by ELISA “postcS_1”
refers to the first postcolostral blood sampling at 1 to 3 days post
partum (p.p.). “postcS_2” refers to a blood sample drawn
approximately 3 months p.p.. “postcS_3” and “postcS_4” refers to
a total of 28 calves where further samples could be taken at later
time points day (between 180 and 387 days p.p.)
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the fetus in later pregnancies, conversely to the situation
found in naturally infected cattle (Gottstein et al. 2005).
As we did not find any significant differences in body
weight between groups I and II, we can claim that treatment
(vero) does directly not have any negative effect on the
gain of body weight, but that a putative effective treatment
of N. caninum also does not affect the body weight gain of
the animals, at last within the time period of 4–6 months.
One question we addressed is if the immediate postnatal
physiology of the digestive system in newborn calves
allows a proper resorption of perorally administered
toltrazuril, thus leading to the appropriate plasma level
required to treat neosporosis. All animals investigated
matched the requirements, and the calves exhibited plasma
levels comparable to those experienced in elder animals
before (Kritzner et al. 2002).
We now initiated a subsequent study to follow up
toltrazuril-medicated calves clinically and serologically
over a longer period, and to investigate if, once they
became themselves animals of breeding age, they give birth
to Neospora-free calves. Therefore, only the comparative
long-term follow-up for more than one generation will help
find the answer.
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